

Marlies van der Goes



Country: Netherlands
Contact e-mail: m.c.vandergoes@umcutrecht.nl
Year of birth: 1984

Mains diplomas:

MD: 2008, Utrecht University, cum laude
Rheumatologist: planned qualification 2018
PhD: 2013, Utrecht University, cum laude
title: Towards safer treatment with glucocorticoids,
promotor: prof. JW Bijlsma, co-promotor: JW Jacobs

Current position and hospital/university:

Rheumatologist in training, University Medical Center Utrecht, Utrecht, The Netherlands

Position within EULAR/international experience:

- Co-author of module "Glucocorticoids" of EULAR Online Course on Rheumatic Diseases (2012-2014)
- Co-author of chapter "Glucocorticoids" of EULAR Textbook on Rheumatic Diseases (2012)
- Research fellow of EULAR Task Force on glucocorticoids (3 projects and 3 publications; 2008-2013)

Role as EMEUNET working group member:

- Member of country liaisons subgroup
- Country liaison for The Netherlands

Areas of Research/Interest: rheumatoid arthritis, treatment strategy, glucocorticoids, osteoporosis

Keywords: rheumatoid arthritis, treatment strategy, glucocorticoids, osteoporosis

Publications:

- van der Goes MC, Strehl C, Buttgerit F, et al. Can adverse effects of glucocorticoid therapy be prevented and treated? Expert Opin Pharmacother. 2016 [Epub ahead of print]
- van der Goes MC, Jacobs JW, Bijlsma JW. Rediscovering the therapeutic use of glucocorticoids in rheumatoid arthritis. Curr Opin Rheumatol. 2016;28:289-96.

- Jurgens MS, Jacobs JW, Boers M, van der Goes MC, et al; Utrecht Arthritis Cohort study group. Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph. *Arthritis Care Res (Hoboken)*. 2015;67:1471-4.
- van der Goes MC, Jacobs JW, Bijlsma JW. The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects. *Arthritis Res Ther*. 2014;16 Suppl 2:S2.
- van der Goes MC, Hoes JN, Cramer MJ, et al. Identifying factors hampering physical activity in longstanding rheumatoid arthritis. *Clin Exp Rheumatol*. 2014;32:155-61.
- Iudici M, van der Goes MC, Valentini G, Bijlsma JW. Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. *Clin Exp Rheumatol*. 2013;31(2 Suppl 76):157-65.
- Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis*. 2013;72:1905-13.
- van der Goes MC, Jacobs JW, Jurgens MS, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? *Osteoporos Int*. 2013;24:1429-36.
- van der Goes MC, Straub RH, Wenting-Van Wijk MJ, et al. Intra-articular glucocorticoid injections decrease the number of steroid hormone receptor positive cells in synovial tissue of patients with persistent knee arthritis. *Ann Rheum Dis*. 2012;71:1552-8.
- Jacobs JW, van der Goes MC, Buttgerit F. Glucocorticoids in rheumatic diseases. In: Bijlsma JWJ, ed. *EULAR textbook on rheumatic diseases*. London: BMJ Group, 2012.
- Spies CM, Strehl C, van der Goes MC, et al. Glucocorticoids. *Best Pract Res Clin Rheumatol*. 2011;25:891-900.
- van der Goes MC, Jacobs JW, Bijlsma JW. Toward safer treatment with glucocorticoids: via patient and rheumatologist perspectives to recommendations on monitoring for adverse events. *Clin Exp Rheumatol* 2011;29(Suppl. 68):S116-20.
- Hoes JN, van der Goes MC, van Raalte DH, et al. Glucose tolerance, insulin sensitivity and {beta}-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. *Ann Rheum Dis*. 2011;70:1887-94.
- Hoes JN, van der Goes MC, Jacobs JW, et al. Changes in macrophage inhibitory factor correlate with changes in bone mineral density in glucocorticoid-treated patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2011;50:1921-4.
- van der Goes MC, Bossema ER, Hartkamp A, et al. Cortisol during the day in chronic patients with systemic lupus erythematosus or primary Sjogren's syndrome. *J Rheumatol*. 2011;38:285-8.
- van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. *Ann Rheum Dis*. 2010;69:1913-9.
- Bijlsma JW, van der Goes MC, Hoes JN, et al. Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. *Ann N Y Acad Sci*. 2010;1193:123-6.
- van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis*. 2010;69:1015-21.

Date of last update of the CV: 2016, September